Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid.
The 10-year survival rate for medullary carcinoma of the thyroid (MCT) is 50%; thus, good tumor-seeking radiopharmaceuticals are needed to localize foci of recurrence and metastasis during follow-up. Two patients with metastatic MCT were studied with Tl-201, I-131 MIBG, Tc-99m (V)-DMSA, and Tc-99m MIBI. A SPECT study with the latter agent allowed the visualization and precise localization of a metastatic mediastinal lymph node. More studies need to be done to evaluate the role of Tc-99m MIBI in the detection of recurrence and metastases of MCT.
Lebouthillier
G
G
Department of Nuclear Medicine, Hôpital Saint-Luc, University of Montreal, Quebec, Canada.
Morais
J
J
Picard
M
M
Picard
D
D
Chartrand
R
R
D'Amour
P
P
D000328:Adult; D000368:Aged; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000556:secondary; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D015609:Organotechnetium Compounds; D004113:Succimer; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D017256:Technetium Tc 99m Sestamibi; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging*; D015899:Tomography, Emission-Computed, Single-Photon
D015609:Organotechnetium Compounds; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D017256:Technetium Tc 99m Sestamibi; D004113:Succimer